Objectives: To investigate the association between inhaled nitric oxide treatment and ICU mortality and 28-day ventilator-free days in pediatric acute respiratory distress syndrome. Design: Retrospective cohort study. A propensity score for inhaled nitric oxide treatment was developed and used in the analysis. Setting: Two quaternary care PICUs. Patients: Children with pediatric acute respiratory distress syndrome.
P ediatric acute respiratory distress syndrome (PARDS) affects 2,000-3,000 children in the United States per year (1) (2) (3) (4) . Children with PARDS have poorly compliant lungs and severe refractory hypoxemia due to heterogeneous alveolar injury. Many critically ill children with PARDS are treated with inhaled nitric oxide (iNO) as a rescue therapy (5) . During early PARDS (the first 2-4 d), inflammation and increased permeability of the alveolar epithelium and capillary endothelium result in alveolar filling and collapse. iNO is a selective pulmonary vasodilator, decreasing pulmonary vascular resistance and improving ventilation-perfusion matching in areas of lung continuing to receive ventilation. As a signaling molecule, iNO also plays a key role in the inflammatory process (6) . iNO is theorized to impact outcomes in PARDS both through improvement of oxygenation and modulation of the inflammatory response.
Although studies in children and adults with acute respiratory distress syndrome (ARDS) have demonstrated iNO treatment results in transient oxygenation improvement, there is little evidence to suggest iNO improves outcomes (mortality or length of mechanical ventilation) in either population. Recently, the Pediatric Acute Lung Injury Consensus Conference (PALICC) recommended consideration of iNO treatment in severe PARDS (5) . However, this recommendation was based on minimal evidence. iNO continues to be used frequently but variably across institutions and providers.
We sought to use existing observational patient level data from two PICUs to determine the association between iNO treatment and PICU mortality and 28-day ventilator-free days (VFDs) in PARDS. We hypothesized iNO treatment would be associated with decreased mortality and more VFD in children with PARDS.
MATERIALS AND METHODS
This was a two-center observational cohort study using existing datasets from Children's Hospital Los Angeles (CHLA) and Children's Hospital of Philadelphia (CHOP). At CHLA, invasively mechanically ventilated children meeting PALICC PARDS criteria and admitted to the PICU between March 2009 and April 2013 were retrospectively identified using oxygenation metrics and evaluation of the medical record as previously described (7, 8) . At CHOP, all children with two Pao 2 / Fio 2 ratios less than 300 admitted to the PICU between July 2011 and June 2015 were screened prospectively, and those who met the 1994 American-European Consensus Conference criteria for ARDS and PALICC PARDS criteria were included (8) (9) (10) . We excluded children less than 1 month or greater than 18 years old, those without an arterial catheter, and those on chronic mechanical ventilation. Children transferred to another ICU prior to extubation were also excluded, as complete data on outcome were unavailable. This study was approved by the CHLA and CHOP Institutional Review Boards with a waiver of consent. Of note, iNO treatment in PARDS is not a U.S. Food and Drug Administration-approved use and is considered off-label.
Variable Definition
The PALICC definition of PARDS for invasively ventilated children requires the acute onset of disease (within 7 d) of a known trigger, the presence of a new chest radiograph infiltrate, an oxygenation index (OI = [mean airway pressure × Fio 2 ]/Pao 2 ) greater than or equal to 4, and respiratory failure not entirely explained by fluid overload or cardiac failure. Early PARDS was defined as the first 72 hours after meeting PARDS criteria. Children who received iNO during this time period were analyzed in the iNO treatment group. Children rarely receive iNO later in the course of PARDS. However, children who did receive iNO after 72 hours were analyzed in the untreated group. The clinical insult triggering PARDS was categorized as one of the following: drowning, trauma, pneumonia, sepsis, or other. Comorbidities were defined as chronic preexisting conditions and were categorized as chronic lung disease, chronic neurologic disease, hematologic/oncologic disease, stem cell transplant, solid organ transplant, or another comorbidity (11) . Children admitted with an acute change in their neurologic status or after cardiac arrest were identified. Vasoactive-Inotrope Score (VIS) was calculated as VIS = dopamine (µg/kg/min) + dobutamine (µg/kg/min) + 10 × epinephrine (µg/kg/min) + 100 × norepinephrine (µg/kg/min) + 100 × phenylephrine (µg/kg/min) + 10 × milrinone (µg/kg/min) + 10,000 × vasopressin (U/kg/min) (12) . The highest VIS within 72 hours of PARDS diagnosis was used for analysis. The initial OI at PARDS diagnosis was used in the analysis. Severity of Illness was measured with 12-hour Pediatric Risk of Mortality (PRISM) III (13) . Nonpulmonary organ failure was defined using pediatric definitions (14) . Nonconventional ventilation was defined as high-frequency ventilation or airway pressure release ventilation. A positive oxygenation response to iNO treatment was defined as a 20% decrease in OI by 6 hours after the initiation of treatment. In children without an available arterial blood gas for OI calculation, oxygen saturation index (OSI) was used (OSI = [mean airway pressure × Fio 2 ]/oxygen saturation) as previously defined (15) .
Outcomes
PICU mortality was our primary outcome. A secondary outcome was VFD defined as the days alive and free of invasive mechanical ventilation in the first 28 days after intubation. Children who died were assigned a VFD of 0.
Statistical Analysis
Statistical analysis was performed with Stata v 15.0 (College Station, TX). The full details of the statistical analysis can be found in the Statistical Supplement (Supplemental Digital Content 1, http://links.lww.com/CCM/D831). We developed a propensity score to estimate the probability of iNO treatment for use in adjusting for confounding variables associated with both the decision to start iNO treatment and mortality. We considered the following covariates for inclusion in the propensity score model: age, weight, PARDS trigger, comorbidities, initial OI, maximal VIS, PRISM III score, acute neurologic injury, cardiac arrest, and admission hospital. Variables with a p value of less than 0.05 were retained in the multivariable model. Two-way interaction terms were assessed between variables in the model, and interaction terms with a p value of less than 0.1 were included in the final propensity score model. Balance of covariates was assessed through graphics and standardized differences, and additional variables were added to the propensity score model as required to achieve balance in an iterative approach. A common region of support was identified for the analysis (children in the treated group with a propensity score higher than any child in the untreated group and children in the untreated group with a propensity score lower than any child in the treated group were eliminated).
The developed propensity score was used in three ways for each outcome: 1) matching, 2) inverse probability weighting, and 3) stratification. The psmatch2 command through STATA was used to match children who did and did not receive treatment with iNO based on propensity score. Children were matched 1:1 without replacement using a nearest neighbor approach. Once a matched sample was formed, the treatment effect was estimated by comparing mortality (mixed effects logistic regression model controlling for matched sample) and VFD (zero inflated negative binomial model (zinb) controlling for matched sample) between the two groups. A zero inflated model was used to model VFD due to the presence of excessive zeros; due to Poisson overdispersion of the data, a negative binomial model was used. Variables with a p value of less than 0.2 association with the outcome (died or VFD) and not included in the propensity score model were considered as possible confounders for the matched analysis models. Variables that changed the iNO effect estimate by greater than 20% were included in the model. As matching decreased the analysis sample size significantly, inverse probability weighting and stratification by the propensity score were also used to analyze the association between iNO treatment and outcome using the entire sample. For consistency among models, the inverse probability weighted and stratification models were adjusted for the same confounding variables identified in the matched analysis.
RESULTS
From the CHLA database of 254 patients, 142 children met inclusion and no exclusion criteria (Supplemental Fig. 1 The final propensity score model included initial OI, maximal VIS, PARDS sepsis trigger, PARDS pneumonia trigger, a hematologic/oncologic comorbidity, having any other comorbidity, cardiac arrest, acute neurologic disease, extrapulmonary organ failures, and admission hospital. There were 464 children (93.2%) who had a propensity score for iNO treatment that fell within the zone of common support (as previously defined) (Supplemental Table 1 , Supplemental Digital Content 3, http://links.lww.com/CCM/D833).
We were able to match 176 children (88 per treatment group) by propensity score. Covariates were adequately balanced between the iNO-treated and untreated matched cohort, with the exception of treatment with nonconventional ventilation and extracorporeal membrane oxygenation (ECMO) ( Table  2 and Fig. 1 ). There was one child in the matched cohort who received iNO after 72 hours and was analyzed as untreated.
After controlling for treatment with nonconventional ventilation and ECMO in the matched cohort, treatment with iNO was not associated with mortality (odds ratio [OR], 1.3 [95% CI, 0.56-3.0]; p = 0.54) ( Table 3) . In a zero inflated negative binomial model creating separate models for 0-28 day VFD and 0 versus some VFD, treatment with iNO was not associated with number of VFD [incidence rate ratio, 0.91 [95% CI, 0.8-1.04]; p = 0.17) or 0 VFD (OR, 1.7 [95% CI, 0.77-3.9]; p = 0.19) after controlling for PRISM III score, treatment with nonconventional ventilation, and treatment with ECMO ( Table 4) .
The effect estimates for the association of iNO with mortality were larger in the inverse probability weighted and the stratification analyses but continued not to be statistically significant (all p > 0.1) ( Table 3) . Treatment with iNO also remained unassociated with number of VFD in the inverse probability weighted and the stratification analyses (all p > 0.2) ( Table 4) . In these analyses, subjects treated with iNO were more likely to have 0 VFD (i.e., die or remain on the ventilator for ≥ 28 d) (p ≤ 0.02) ( Table 4) .
In a sensitivity analysis, when we limited the analysis to only children with moderate or severe PARDS, iNO treatment was not associated with either mortality or VFD (all p > 0.1) (Supplemental Tables 2 
DISCUSSION
Our results demonstrate consistently that iNO treatment is not associated with significant improvement in mortality or VFD in PARDS. This is the first retrospective study to use highly granular patient level data to evaluate the effect of iNO treatment on mortality and VFD in PARDS. We accounted for multiple confounding variables on the relationship between iNO and mortality including those that have a strong history of association with poor outcome in PARDS (OI, VIS, and hematologic/oncologic disease). Furthermore, we used the developed propensity score in multiple ways to assess the relationship between iNO treatment and outcome.
A previous randomized, controlled trial of iNO treatment in children with PARDS highlights struggles with enrollment that have impacted the ability to prospectively evaluate the association between iNO treatment and outcomes in PARDS (16) . This study had a planned enrollment of 338 children but only enrolled 55 children from nine centers over a 2-year period presumably due to a lack of clinical equipoise and was therefore stopped for slow enrollment. The authors found a difference in their primary outcome of VFD which just reached statistical significance (iNO treatment 14.2 ± 8.1 d vs control 9.1 ± 9.5 d; p = 0.05).
Although we hypothesized that iNO treatment was associated with benefit in PARDS, in some of the models, we found a suggestion of potential harm (more likely to have 0 VFDs). Although residual confounding may explain this result, there are reasons iNO treatment could be associated with true harm. Due to the concern for rebound pulmonary hypertension, it is common practice to slowly wean iNO. Therefore, children treated with iNO may require longer mechanical ventilation simply for weaning of the drug. In addition, there is emerging literature from adult studies of ARDS that iNO treatment is associated with renal failure and an increased need for renal replacement therapy (17) . We did not specifically study renal impairment as an outcome in our study. Gupta et al (18) recently investigated the association between iNO treatment and outcomes in PARDS using a large database created by linking data from the Virtual Pediatric Systems (VPS) and Pediatric Health Information System (PHIS). They created a propensity score to match children and control for confounding variables influencing the decision to initiate iNO treatment. Unfortunately, as both the VPS and the PHIS databases are primarily administrative databases, the authors were unable to verify children met PARDS criteria, and they did not have data on PARDS severity or degree of hemodynamic instability. The inability to control for these important confounding variables led to this study being criticized by the pediatric critical care community (19) . When examining the subjects enrolled in their study, many of them (58%) were treated with antiarrhythmics which is unusual for PARDS and indicates a different study population than our study. The results for our primary outcome were similar; no significant difference in mortality. However, in contrast to our primary analysis results, the study by Gupta et al (18) found a significant association between iNO treatment and fewer VFD. This difference may be due to actual harm in their study population or the inability of their developed propensity score to adequately control for confounding variables in the matched sample. Dowell et al (19) recently found that children with a positive oxygenation response to iNO may be most likely to benefit from treatment (fewer ventilator days). We did not find similar results in our analysis with a positive oxygenation response not being associated with benefit. Rather the children who did not have a positive oxygenation response had evidence of harm (more 0 VFD). It is possible that the lack of an oxygenation response simply identifies children with more severe lung injury who may have worse outcomes regardless of iNO treatment. On the other hand, it is important to consider that although the heterogeneous general population of children with PARDS may derive no benefit from iNO, there may be discrete subgroups who respond either positively or negatively. Identifying markers that may identify these subgroups will be important for future trials.
We chose to use a zero inflated negative binomial model for VFD. This model combines separate models for 0-28-day VFD and 0 VFD. The composite outcome of 0 VFD comprises both children who die and those who receive mechanical ventilation for greater than or equal to 28 days. We found in the matched primary analysis no association between 0 VFD and iNO treatment; however, we did find a statistically significant association with more 0 VFD in the stratification and inverse probability weighted analyses. The reason for this discrepancy may be that the stratification and inverse probability weighted analyses were more adequately powered to detect the association or that these methods do not adequately balance on propensity score. Overall, in their entirety, our results consistently demonstrate no significant benefit to iNO treatment and the possibility of harm.
iNO treatment is also associated with exorbitant costs, often not reimbursed by insurance companies as treatment in PARDS is not an FDA-approved indication (20) . The results of this analysis and others call into question the relatively routine practice of prolonged iNO treatment in children with PARDS. Although the PALICC recommendations suggest considering iNO treatment in severe PARDS, this recommendation was based on minimal evidence, and our analysis points toward no benefit in the moderate/severe PARDS group. A costly therapy with no definitive evidence for benefit and the possibility of harm is not likely to survive in an era of cost cutting. Although a classic randomized controlled trial is probably unlikely to achieve adequate enrollment, newer more innovative clinical trial designs particularly with regard to protocolized rescue therapies have the potential for increased acceptability to clinicians and should be considered by the pediatric critical care community (21) . Although this study represents a robust analysis of available observational data, there were several limitations. Although we controlled for all available clinical or management variables associated with either the decision to start iNO treatment or mortality, it is possible there are unmeasured influential clinical or management variables we were unable to control for in our propensity score model. If these unknown clinical or management variables are associated with both the decision to initiate iNO treatment and either mortality or fewer VFD, this could have led to us not identifying a true benefit from iNO treatment. We combined prospectively collected data from one hospital with retrospectively collected data from another hospital to perform this analysis; therefore, it is possible selection bias affected our results although we attempted to decrease this risk by including admission hospital as a variable in the propensity score model. Furthermore, we were able to match only 61.5% of the children who received iNO with children who did not receive iNO in our primary analysis. This study was therefore powered to identify large changes in mortality or VFD, and it is possible a smaller effect was not identified; nonetheless, the estimate of association was in the direction of higher mortality and fewer VFD in the iNO-treated children. It is also possible that the association between iNO treatment and outcome could be different in the children who were not matched, or the children who were not in the region of common support, and the generalizability of our findings may be limited.
CONCLUSIONS
This large observational study demonstrates iNO treatment in PARDS is not associated with a significant improvement in either mortality or VFD and may be associated with harm. As a costly treatment that remains frequently used for PARDS, this study in combination with other recent studies calls attention to the need for clinical equipoise for future clinical trial enrollment.
